Regulatory Focus™ > News Articles > FDA Gets Permanent Director for Reorganized Surveillance 'Super Office'

FDA Gets Permanent Director for Reorganized Surveillance 'Super Office'

Posted 12 June 2012 | By Alexander Gaffney, RAC 

The US Food and Drug Administration (FDA) has announced the promotion of Gerald Dal Pan, MD to the position of permanent director of FDA's Office of Surveillance and Epidemiology (OSE), where Dal Pan had been serving as acting director.

OSE had recently undergone a reorganization that transformed it from a relatively minor office within the Center for Drug Evaluation and Research (CDER) and into a so-called "super office." Dal Pan has served as the head of OSE since 2005, and was made acting director of the new office when it was reorganized in June 2011.

In an email announcing the promotion of Dal Pan, CDER Director Janet Woodcock said he has overseen OSE during a period in which the office's staff grew from 116 to more than 250, and has been instrumental in leading FDA's postmarket safety initiatives.

Read more:

Woodcock's letter (via

Dal Pan on Drug Safety in May 2012

Regulatory Focus newsletters

All the biggest regulatory news and happenings.